Parikh RC, Niyazov A, Esterberg E, Arondekar B, Hitchens A, Shahied Arruda L, Obeid E. Patient (Pt) demographics, clinical characteristics and treatment patterns among pts with Germline Breast Cancer Susceptibility Gene 1/2 mutated (gBRCA1/2mut) HER2– Advanced Breast Cancer (ABC): results from a US real-world study. Poster presented at the 2020 Miami Breast Cancer Conference; March 5, 2020. Miami Beach, FL.

BACKGROUND: Germline BRCA1/2mut breast cancer (BC) represents ~5% of all BC. Historically, chemotherapy (CT) and/or endocrine therapy was commonly used in these pts, but targeted treatments (poly ADP-ribose polymerase inhibitors [PARPi]) have become recently available. This study assessed real-world pt demographics, clinical characteristics, and treatment patterns across different lines of therapy (LOT) among US pts with gBRCA1/2mut HER2– ABC.

MATERIALS AND METHODS: Oncologists retrospectively reviewed charts (July-Oct 2019) of randomly selected pts ≥18 yrs, with HER2 gBRCA1/2mut ABC who received ≥1 cytotoxic CT regimen(s) for ABC between Jan 2013-Apr 2018. Pt demographics/clinical characteristics were measured at ABC diagnosis. Pt characteristics and regimens for the 1st 3 LOT for ABC were descriptively summarized.

RESULTS: 177 pts were included: 99.4% were female, 78.5% were white, 11.3% had Ashkenazi Jewish descent. No known family history (FH) of BRCA-related cancer(s) was reported by 27.7% of pts. Median age was 58.0 yrs. 62.1% had advanced triple-negative BC (TNBC) and 37.9% had hormone receptor (HR)+/HER2– ABC. Common comorbidities in 64.4% of pts included hypertension (37.3%), depression (25.4%), and diabetes (15.8%). Frequency of treatments varied by LOT (Table 1). Treatment patterns by different years will be presented.

CONCLUSIONS: In gBRCA1/2mut HER2- ABC pts, comorbidities were commonly reported, and a significant proportion of the pts had no known FH of BRCA-related cancer(s). Frequency of treatments varied by LOT. Testing all pts with ABC for gBRCA1/2mut should be considered. Pt characteristics, including comorbidities, should be considered when evaluating treatment options, since targeted treatments with improved efficacy and favorable pt reported outcomes are now available.

Share on: